HER2 negative breast cancer, displayed evidence of anti-tumor activity and signs of strong efficacy. The data showed three PRs (partial responses), of which one was confirmed, and a 42% clinical benefit rate. Oppenheimer analyst Mark Breidenbach calls the data “highly encouraging.
https://blog.tipranks.com/?p=110635